Rejuvenation Technologies is a biotechnology company that developed nucleoside-modified TERT mRNA to safely and rapidly extend telomeres.
Rejuvenation Technologies has raised $2.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in September 2026.
Rejuvenation Technologies's investors include Khosla Ventures, Y Combinator, National Institutes of Health, Reinforced Ventures, Longevitytech.fund.
Rejuvenation Technologies is headquartered in Mountain View, United States.
Rejuvenation Technologies is a biotechnology company that developed nucleoside-modified TERT mRNA to safely and rapidly extend telomeres.
Rejuvenation Technologies is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Rejuvenation Technologies — Funding & Investors." VCBacked, September 16, 2026, https://www.vcbacked.co/company/rejuvenation-technologies. Accessed November 13, 2026.
VCBacked. (2026). Rejuvenation Technologies — Funding & Investors. Retrieved November 13, 2026, from https://www.vcbacked.co/company/rejuvenation-technologies
{{cite web |title=Rejuvenation Technologies — Funding & Investors |url=https://www.vcbacked.co/company/rejuvenation-technologies |website=VCBacked |access-date=November 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Rejuvenation Technologies? Request a listing update